entrectinib has been researched along with Carcinoma--Acinar-Cell* in 1 studies
1 other study(ies) available for entrectinib and Carcinoma--Acinar-Cell
| Article | Year |
|---|---|
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).
Mammary analogue secretory carcinoma (MASC) is a recently described pathologic entity. We report the case of a patient with an initial diagnosis of salivary acinic cell carcinoma later reclassified as MASC after next-generation sequencing revealed an ETV6-NTRK3 fusion.. This alteration was targeted with the pan-Trk inhibitor entrectinib (Ignyta), which possesses potent in vitro activity against cell lines containing various NTRK1/2/3 fusions.. A dramatic and durable response was achieved with entrectinib in this patient, followed by acquired resistance that correlated with the appearance of a novel NTRK3 G623R mutation. Structural modeling predicts that this alteration sterically interferes with drug binding, correlating to decreased sensitivity to drug inhibition observed in cell-based assays.. This first report of clinical activity with TrkC inhibition and the development of acquired resistance in an NTRK3-rearranged cancer emphasize the utility of comprehensive molecular profiling and targeted therapy for rare malignancies (NCT02097810). Topics: Adult; Benzamides; Biomarkers, Tumor; Carcinoma, Acinar Cell; Clinical Trials as Topic; Crizotinib; Diagnosis, Differential; Drug Resistance, Neoplasm; Female; Humans; In Situ Hybridization, Fluorescence; Indazoles; Mammary Analogue Secretory Carcinoma; Mutation; Oncogene Proteins, Fusion; Pyrazoles; Pyridines; Salivary Gland Neoplasms | 2016 |